BerGenBio AS is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for aggressive cancers. The Company is a world leader in understanding the biology of epithelial-mesenchymal transition (EMT), which is widely recognized as a key pathway in immune evasion, acquired cancer drug-resistance and metastasis. Building on this original biological insight BerGenBio is developing a promising pipeline of first-in-class EMT inhibitors.

UniTargetingResearch AS provides the biopharmaceutical industry with tools and services bringing down the manufacturing cost and cycle times for therapeutic proteins produced in mammalian cell-lines. The company holds superior IP and know-how in the area of post- transcriptional regulation in mammalian cells, and is working closely with Novartis Pharma.

Balter Medical AS a medical technology company developing the medical applications of the Optical Transfer Theory, a mathematical modeling technique using digital photographic images (pictures) to understand the properties of the subject in the picture. Balter Medical AS has successfully developed a rigorous medical imaging device & diagnostic algorithm, called Optical Transfer Diagnosis (OTD), for detecting anomalies in human tissue.

ScreenCancer AS aims to augment global cancer screening rates by creating screening management services tailored to the needs of health plans, self-insured employers, and private individuals. The company has positioned it self as a supplier of a molescreening service to the worlds leading pharmacy chain Walgreens Boots Allianse.

Epsis AS is a leader in Operational Excellence, Integrated Operations and Collaborative Working. The Epsis Teambox software is delivering real changes in operational performance, collaboration, information management, decision-making to clients as Chevron, Statoil, ConocoPhillips, Total, Saudi Aramco and Halliburton

Sarsia Seed AS is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors. The fund has 13 active investments, of which 5 has a promising pipeline of novel pharmaceutical drugs.